Sahm Adrangi is known for making predictions about the financial state of companies well before it was put into action. One of the most recent predictions that he made was about the recent stream of biotech disasters which swayed the industry. One of the predictions that Sahm Adrangi had made was about a cancer vaccine that was being released by Bavarian Nordic, which outlined that the vaccine was nothing more than a pure placebo, with no actual medical basis covering it. This isn’t the only prediction that is being made instead of this. He also made a prediction regarding Prothena, stating that the company’s lead drug is bound to fail in due course of time, and is something that will cause the downfall, at least of that manufacturing segment within the company.
Sahm Adrangi conducted an analysis through Kerrisdale Capital Management and soon found out that the initial phases of the drug trial were inconclusive in shedding light on any evidence that would suggest the success of the drug. It showcased that the drug showed more disbelief than any conclusive evidence of working on what it was intended to do, which is why it would probably not have a very favorable outcome in the market and once people started to realize that something like this would not work well. This will inevitably also lead to a huge amount of financial losses for the company because as it currently stands, the drugs their flagship product.
Since Adrangi released a report about this investigation, Prothena has experienced a considerable drop in their share price. It is evident that this information has informed more people about the probability of the drug working, which has, in turn, had an impact on the investments that people want to make into this. Go To This Page for related information.
Kerrisdale Capital Management is a company that conducts research and analysis of corporate giants to point out their financial conditions, and to can provide a more thorough basis of information for investment purposes. The company was first formed by Sahm Adrangi in 2009 and since then has published work on various websites, publications, and has worked individually with corporates who want to conduct their financial analysis.